Braunstein now CMO at Idorsia
Plus Kush, Haddach join RayzeBio and updates from Coherus, InterVenn, AsherBio and more
Guy Braunstein will assume the newly created role of CMO at Idorsia Ltd. (SIX:IDIA), handing off his job as head of global clinical development to Alberto Gimona, the company’s head of therapeutic area units. Gimona will also join Braunstein on Idorsia’s executive committee. Braunstein has headed global clinical development at the company since it was founded; Gimona joined from Actelion Ltd. in February 2019 — the company that Idorsia was spun out of after Johnson & Johnson (NYSE:JNJ) acquired it in 2017.
Radiopharmaceutical company RayzeBio Inc. hired Arvind Kush as CFO and Aubrey Haddach as general counsel. Kush joins the company from Bank of America Securities, where he was managing director in the healthcare investment banking group. Haddach was a medicinal chemist at Neurocrine Biosciences Inc. (NASDAQ:NBIX) who subsequently became a patent agent, then patent attorney. She joins RayzeBio from Ansun Biopharma Inc. where she was general counsel. RayzeBio raised a $108 million series C round in June 2021. ...